Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil

Rheumatology

Volumn 49, Issue 11, 2010, Pages 2061-2067

  Schaier, Matthias ^a   Scholl, Christian ^a   Scharpf, Dominik ^a   Hug, Friederike ^a   Bönisch Schmidt, Sabine ^a   Dikow, Ralf ^a   Schmitt, Wilhelm H ^b   Schwenger, Vedat ^a   Zeier, Martin ^a   Sommerer, Claudia ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Autoimmune disease; Inosine 5' monophosphate dehydrogenase; Mycophenolic acid; Therapeutic drug monitoring

Indexed keywords

ANTACID AGENT; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANTOPRAZOLE;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG POTENCY; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AUTOIMMUNE DISEASES; CHI-SQUARE DISTRIBUTION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 78649355482     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq238     Document Type: Article

References (39)

1. Stassen PM, Kallenberg CG, Stegeman CA. Use of mycophenolic acid in non-transplant renal diseases. Nephrol Dial Transplant 2007;22:1013-9.
2. Knight SR, Russell NK, Barcena L, Morris PJ. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 2009;87:785-94.
3. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008;23:1307-12.
4. Hiemstra TF, Walsh MW, Schmitt W, Jayne DRW. Randomised controlled trial of mycophenolate mofetil versus azathioprine for maintenance therapy in ANCA-associated vasculitis (IMPROVE). J Am Soc Nephrol 2009;SA-FC331:77 (Abstracts Issue 20).
5. Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
6. Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology 2009;48:944-52.
7. de Winter BC, van Gelder T. Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases. Nephrol Dial Transplant 2008;23:3386-8.
8. Bullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol 1996;41:513-6.
9. Lidgate D, Brandl M, Holper M, Abubakari A, Wu X. Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil. Drug Dev Ind Pharm 2002; 28:1275-83.
10. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47: 85-118.
11. Neumann I, Haidinger M, Jager H et al. Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. J Am Soc Nephrol 2003;14:721-7.
12. Neumann I, Fuhrmann H, Fang IF, Jaeger A, Bayer P, Kovarik J. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dial Transplant 2008;23:3514-20.
13. Yatscoff RW, Aspeslet LJ, Gallant HL. Pharmacodynamic monitoring of immunosuppressive drugs. Clin Chem 1998; 44:428-32.
14. Budde K, Glander P, Bauer S et al. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 2000;38:1213-6.
15. Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
16. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
17. Glander P, Braun KP, Hambach P et al. Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem 2001;34:543-9.
18. Sommerer C, Müller-Krebs S, Schaier M et al. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol 2010;69:346-57.
19. Martin RM, Lim AG, Kerry SM, Hilton SR. Trends in prescribing h2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther 1998; 12:797-805.
20. Ntaios G, Chatzinikolaou A, Kaiafa G, Savopoulos C, Hatzitolios A, Karamitsos D. Evaluation of use of proton pump inhibitors in Greece. Eur J Intern Med 2009;20: 171-3.
21. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 2001;23:116-7.
22. Jungnickel PW. Pantoprazole: a new proton pump inhibitor. Clin Ther 2000;22:1268-93.
23. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol 2009; 104(Suppl. 2):S27-32.
24. Tutuian R, Katz PO, Bochenek W, Castell DO. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. Aliment Pharmacol Ther 2002;16:829-36.
25. Hartmann M, Theiss U, Huber R et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996;10:359-66.
26. Miura M, Satoh S, Inoue K et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit 2008; 30:46-51.
27. del Mar Fernandez De Gatta M, Santos-Buelga D, Dominguez-Gil A, Garcia MJ. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 2002;41:115-35.
28. Tomiyama Y, Morii M, Takeguchi N. Specific proton pump inhibitors e3810 and lansoprazole affect the recovery process of gastric secretion in rats differently. Biochem Pharmacol 1994;48:2049-55.
29. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996;36: 315-24.
30. de Winter BC, Neumann I, van Hest RM, van Gelder T, Mathot RA. Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease. Ther Drug Monit 2009; 31:382-90.
31. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62:1060-7.
32. Rupprecht K, Schmidt C, Raspe A et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol 2009;49:1196-201.
33. Kofler S, Shvets N, Bigdeli AK et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. Am J Transplant 2009;9:1650-6.
34. van Gelder T. Mycophenolate mofetil: how to further improve using an already successful drug? Am J Transplant 2005;5:199-200.
35. Glander P, Hambach P, Braun KP et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004;4:2045-51.
36. Budde K, Glander P, Kramer BK et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation 2007;83:417-24.
37. Schaier M, Scharpf D, Scholl C et al. Predose IMPDH activity is not influenced by underlying renal disease. NDT Plus 2008;1:ii408.
38. Budde K, Bauer S, Hambach P et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007;7:888-98.
39. Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 1996;62:666-72.